Garadacimab-gxii Drug Asset Due Diligence Report 2026

This Garadacimab-gxii Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Garadacimab-gxii can convert its Monoclonal antibody profile and Factor XIIa biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Garadacimab-gxii (query alias: garadacimab)
Modality / target	Monoclonal antibody; Factor XIIa; Factor XIIa inhibitors
Highest global status	Approved
Originator	CSL Behring LLC
Active developers	CSL Behring LLC, CSL Behring KK, CSL Behring (Australia) Pty Ltd.

The MCP disease footprint includes Hereditary Angioedema. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06806657	Phase 4	Active, not recruiting	18	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NL-OMON58463	Phase 4	Pending	5	Not disclosed
NCT05819775	Phase 3	Completed	22	Number of Participants With Treatment Emergent Adverse Events (TEAE)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema

Phase 3; n=171; evaluation: not stated. Reported fields: -; Number of Participants With Treatment-emergent Adverse Events (TEAE) = 146 Participants ; -

A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age

Phase 3; n=22; evaluation: not stated. Reported fields: Number of Participants With Treatment Emergent Adverse Events (TEAE) = 11 Participants ; Number of Participants With Treatment Emergent Adverse Events (TEAE) = 5 Participants ; -

Safety and Efficacy in Patients With Hereditary Angioedema After Switching to Garadacimab: Interim Analysis of a Phase 4, Open-Label Study

Phase 4; n=6; evaluation: Positive. Reported fields: TEAE = 1.0 events

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Garadacimab-gxii addresses Hereditary Angioedema. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Factor XIIa records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2020-09-21	Bridge Medicines and The Rockefeller University collaborate to advance the development of a series of small molecule inhibitors targeting Factor XII (FXIIa) for the treatment of hereditary angioedema (HAE).	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “High concentration formulation of factor xii antigen binding proteins”. The milestone feed surfaced a patent-application signal described as “Use of an Anti-factor xii antibody for the treatment or prevention of hereditary angioedema”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO